Does fatty liver affect your immune system? Yes, fatty liver disease significantly impacts immune function through chronic inflammation and altered immune cell activity. When excess fat accumulates in liver cells—a condition affecting 20–30% of UK adults—it triggers inflammatory responses that extend beyond the liver itself. The liver houses the body's largest population of tissue-resident immune cells (Kupffer cells), which become chronically activated in fatty liver disease, releasing inflammatory molecules that affect systemic immunity. This bidirectional relationship means metabolic dysfunction triggers immune changes, whilst immune dysregulation worsens liver fat accumulation. Understanding how fatty liver affects immunity is essential for preventing disease progression and managing associated health risks, including cardiovascular disease and potential infection susceptibility.

Understanding Fatty Liver Disease and Immune Function

Fatty liver disease, medically termed hepatic steatosis, occurs when excess fat accumulates in liver cells, typically affecting 5% or more of hepatocytes (liver cells) or when liver fat content exceeds 5% on MRI proton density fat fraction (MRI-PDFF) measurement. This condition exists in two primary forms: non-alcoholic fatty liver disease (NAFLD), which affects individuals who consume little to no alcohol (less than 14 units weekly for women, less than 21 units for men), and alcohol-related liver disease (ARLD), directly linked to excessive alcohol consumption. NAFLD has become increasingly prevalent in the UK, affecting approximately 20–30% of adults, often associated with obesity, type 2 diabetes, and metabolic syndrome. Newer international literature may use the term metabolic dysfunction-associated steatotic liver disease (MASLD), though NICE currently uses NAFLD terminology.

Diagnosis of NAFLD requires exclusion of significant alcohol intake and other causes of fatty liver, such as viral hepatitis, certain medications, or hereditary conditions. The condition is often detected incidentally through abnormal liver function tests or imaging performed for other reasons.

The liver serves as a crucial immunological organ, functioning as the body's primary filter for blood arriving from the digestive system. It contains specialised immune cells called Kupffer cells, which represent the largest population of tissue-resident macrophages in the human body. These cells continuously monitor blood for pathogens, toxins, and cellular debris whilst regulating inflammatory responses throughout the body.

When fat accumulates in liver tissue, it can alter the organ's normal architecture and cellular function. This disruption may affect not only the liver's metabolic duties—such as processing nutrients, producing proteins, and detoxifying harmful substances—but also its immunological capabilities. The relationship between fatty liver and immune function is bidirectional: metabolic dysfunction can trigger immune changes, whilst immune dysregulation may worsen liver fat accumulation.

Research has increasingly demonstrated that fatty liver disease can have systemic effects that extend throughout the body, with the immune system being particularly affected by these changes. Understanding this connection is essential for both preventing disease progression and managing associated health risks.

How Fatty Liver Affects Your Immune System

Fatty liver disease is associated with changes in immune system function through several interconnected mechanisms, though the degree of impact varies by disease severity. The accumulation of fat within hepatocytes triggers cellular stress responses, causing these cells to release inflammatory signals that activate the liver's resident immune cells. Kupffer cells, normally responsible for maintaining immune tolerance and clearing debris, may become chronically activated and begin producing pro-inflammatory molecules called cytokines, including tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6).

This chronic activation can alter the liver's immune landscape. Rather than responding appropriately to genuine threats, the immune system may enter a state of persistent low-grade inflammation. Natural killer (NK) cells, which normally destroy virus-infected and cancerous cells, may show altered function in fatty liver disease, though evidence is mixed and further research is needed to establish clinical significance. Some studies have suggested that individuals with NAFLD demonstrate changes in NK cell activity compared to those with healthy livers.

The immune changes may extend beyond the liver itself. Fat accumulation, particularly in the visceral (abdominal) region often accompanying fatty liver, releases additional inflammatory mediators into the bloodstream. This can create systemic inflammation that affects immune responses throughout the body. The gut–liver axis also plays a role: increased intestinal permeability (sometimes referred to as 'leaky gut' in non-medical contexts) may allow bacterial products to enter the bloodstream and reach the liver, further stimulating immune activation.

In advanced liver disease and cirrhosis, the liver's ability to produce essential immune proteins, including complement components and acute-phase reactants, may become impaired. However, this typically occurs only with significant liver dysfunction. Complement pathways may be dysregulated in fatty liver disease, though the clinical implications are still being investigated.

Emerging evidence suggests that immune changes in fatty liver disease might influence susceptibility to certain infections, though this relationship is not yet fully established and is not currently part of routine UK clinical decision-making. Some research has indicated that individuals with NAFLD may experience more severe outcomes from certain respiratory infections, but further studies are needed to confirm these associations.

Inflammation and Immune Response in Fatty Liver

The inflammatory process in fatty liver disease represents a complex cascade involving multiple immune cell types and signalling pathways. Initially, fat accumulation causes lipotoxicity—direct cellular damage from excess lipids—which triggers hepatocytes to release danger signals. These signals recruit additional immune cells from the bloodstream, including monocytes that differentiate into pro-inflammatory macrophages upon entering the liver tissue.

As inflammation persists, the condition may progress from simple steatosis (fat accumulation alone) to non-alcoholic steatohepatitis (NASH), characterised by hepatocyte injury, inflammation, and often fibrosis (scarring). Under newer international nomenclature, NASH is termed metabolic dysfunction-associated steatohepatitis (MASH); NICE currently uses NAFLD and NASH terminology. This progression involves the activation of hepatic stellate cells, which normally store vitamin A but transform into collagen-producing cells in response to chronic inflammation. The resulting fibrosis represents the immune system's attempt to contain damage but ultimately impairs liver function.

The inflammatory mediators produced in fatty liver disease don't remain localised. C-reactive protein (CRP), an inflammatory marker produced by the liver in response to IL-6, may become elevated in some individuals with NAFLD and can be detected through blood tests. However, CRP is non-specific and is not used to diagnose NAFLD or to stage fibrosis in UK practice. Elevated CRP levels indicate systemic inflammation and are associated with increased cardiovascular risk, highlighting how liver-based immune activation may affect overall health.

Chronic inflammation also promotes insulin resistance, creating a vicious cycle. Inflammatory cytokines interfere with insulin signalling pathways, making it harder for cells to respond to insulin. This worsens metabolic dysfunction, leading to further fat accumulation in the liver and perpetuating immune activation. The interplay between metabolic and immune pathways in fatty liver disease demonstrates why the condition is increasingly viewed as a systemic disorder rather than an isolated liver problem.

Importantly, the degree of inflammation varies considerably between individuals. Some people maintain simple steatosis for years without progression, whilst others develop aggressive inflammation and fibrosis. Recognised risk factors for progression include type 2 diabetes, metabolic syndrome, older age, obesity, and genetic variants such as PNPLA3. Environmental exposures, gut microbiome composition, and concurrent health conditions also influence individual inflammatory responses.

Complications of Immune System Changes

The immune alterations associated with fatty liver disease contribute to numerous health complications, some directly related to liver function and others affecting distant organ systems. Progressive liver disease represents the most direct consequence: chronic immune activation and inflammation can lead to advanced fibrosis, cirrhosis (severe scarring), and in some cases, hepatocellular carcinoma (liver cancer). NICE guidelines emphasise the importance of identifying individuals with advanced fibrosis, as they face significantly increased risks of liver-related morbidity and mortality.

In UK primary care, initial risk stratification uses validated scores such as the FIB-4 index or NAFLD Fibrosis Score. If these scores are indeterminate or high, the Enhanced Liver Fibrosis (ELF) blood test is offered. Individuals with an ELF score of 10.51 or above, or persistently high-risk scores, should be referred to hepatology services. Transient elastography (FibroScan) may also be considered to assess liver stiffness and guide management.

Cardiovascular disease emerges as the leading cause of death in individuals with NAFLD, partly mediated by immune dysfunction. The systemic inflammation associated with fatty liver promotes atherosclerosis (arterial plaque formation), increases blood clotting tendency, and contributes to endothelial dysfunction (impaired blood vessel function). Inflammatory cytokines from the liver enter the circulation and may directly affect blood vessel walls, whilst altered lipid metabolism further compounds cardiovascular risk.

Emerging evidence suggests that immune changes in fatty liver disease might influence susceptibility to certain infections, though this relationship requires further research and is not yet established. The altered function of immune cells, combined with potential impairments in the liver's ability to clear pathogens in advanced disease, may affect how the body responds to bacterial and viral challenges. Some studies have indicated that individuals with NAFLD may experience more severe outcomes from respiratory infections, though evidence is still evolving.

Type 2 diabetes and fatty liver disease share bidirectional relationships mediated partly through immune pathways. Chronic inflammation worsens insulin resistance, whilst diabetes accelerates liver disease progression. Additionally, the immune dysfunction may contribute to other metabolic complications, including dyslipidaemia (abnormal blood lipid levels) and hypertension.

Patients should contact their GP if they experience symptoms suggesting liver disease progression, including persistent fatigue, unexplained weight loss, abdominal swelling, easy bruising, or itching. Seek same-day GP or NHS 111 advice if you develop new jaundice (yellowing of skin or eyes), rapidly worsening abdominal swelling, or fever with abdominal pain. Call 999 or go to A&E immediately if you experience confusion or drowsiness, vomit blood or pass black tarry stools, have severe abdominal pain, or develop breathlessness from abdominal swelling. These may indicate serious complications requiring urgent assessment.

Individuals with cirrhosis require specialist hepatology input and enhanced surveillance for complications. NICE guidance (NG50) recommends 6-monthly ultrasound surveillance for hepatocellular carcinoma in people with cirrhosis.

Managing Fatty Liver to Support Immune Health

Managing fatty liver disease to support immune function centres on addressing underlying metabolic dysfunction and reducing hepatic inflammation. Weight loss represents the most evidence-based intervention for NAFLD. Studies demonstrate that losing 7–10% of body weight can significantly reduce liver fat, improve inflammatory markers, and even reverse fibrosis in some individuals. NICE recommends structured weight management programmes combining dietary modification with increased physical activity as first-line treatment.

Dietary approaches should focus on overall nutritional quality rather than extreme restrictions. The Mediterranean diet, rich in vegetables, fruits, whole grains, legumes, nuts, and olive oil, with moderate fish consumption and limited red meat, has shown particular promise in reducing liver fat and inflammation. Avoiding added sugars, particularly fructose-containing beverages, and limiting saturated fats helps reduce hepatic lipid accumulation. Some evidence suggests that coffee consumption may have protective effects on liver health, though this should complement rather than replace other lifestyle measures.

Regular physical activity benefits fatty liver disease through multiple mechanisms. Exercise improves insulin sensitivity, reduces visceral fat, and has direct anti-inflammatory effects. The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity weekly (or 75 minutes of vigorous activity), combined with muscle-strengthening activities on two or more days. Importantly, exercise can improve liver fat even without significant weight loss.

For individuals with concurrent conditions, optimal management of diabetes, hypertension, and dyslipidaemia is essential for overall cardiovascular and metabolic health. Statins are safe in NAFLD and should not be withheld when indicated for dyslipidaemia or cardiovascular risk reduction based on QRISK assessment. Metformin is used for glycaemic control in type 2 diabetes but is not recommended specifically to treat NAFLD.

No medications are currently licensed specifically for NAFLD treatment in the UK. However, NICE guidance (NG49) suggests that specialists may consider pioglitazone (in adults with biopsy-proven NASH without cirrhosis) or vitamin E (in selected non-diabetic adults with biopsy-proven NASH) on an off-label basis. These decisions are made in specialist hepatology settings after careful assessment.

Patients should avoid hepatotoxic substances, particularly excessive alcohol consumption, which can accelerate liver damage. The UK Chief Medical Officers recommend not regularly drinking more than 14 units of alcohol weekly, spread over three or more days with several alcohol-free days. Individuals with alcohol-related liver disease should abstain completely and seek support from their GP or local alcohol services. Exercise caution with herbal supplements, as some may cause drug-induced liver injury; discuss all supplements with your GP or pharmacist.

Regular monitoring is important. In UK primary care, adults with NAFLD should have their fibrosis risk reassessed approximately every three years using FIB-4 or NAFLD Fibrosis Score. The ELF blood test and/or transient elastography (FibroScan) are used when scores are indeterminate or high. Referral to hepatology is recommended if the ELF score is 10.51 or above, or if other high-risk features are present.

People with chronic liver disease should ensure they are up to date with vaccinations, including annual influenza, pneumococcal, COVID-19, and hepatitis A and B vaccines as recommended in the UK immunisation schedule (Green Book).

If you experience a suspected side effect from any medicine, vaccine, or herbal product, you can report it via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or by searching for 'Yellow Card' in the Google Play or Apple App Store.

Frequently Asked Questions